Today: 20 March 2026
Browse Category

NASDAQ:LGF.B 29 December 2025 - 31 December 2025

Lionsgate Studios stock today: LION slides after insider sale filings hit the tape

Lionsgate Studios stock today: LION slides after insider sale filings hit the tape

Lionsgate Studios shares dropped 3.4% to $8.94 midday after SEC filings showed CEO Jon Feltheimer and Vice Chair Michael Burns sold stock in late December for tax planning. Feltheimer sold 195,000 shares at $8.28, Burns sold 21,748 at $9.01. The stock traded between $8.94 and $9.16 on volume of 1.23 million shares. Investors are watching if shares hold below $9 ahead of the next earnings update.
Tyler Perry lawsuit names Lionsgate, putting Lionsgate Studios stock in focus before the open

Tyler Perry lawsuit names Lionsgate, putting Lionsgate Studios stock in focus before the open

Lionsgate Studios shares closed up 4.6% at $9.31 Friday as investors weighed a new lawsuit naming the company and filmmaker Tyler Perry as defendants. Actor Mario Rodriguez filed suit in California, seeking at least $77 million and alleging unwanted sexual advances by Perry and negligence by Lionsgate. The company did not immediately comment. Trading resumes Monday with investors watching for a response.

Stock Market Today

  • Centene Launches Community Programs Amid Depressed Stock Price: What Investors Should Know
    March 20, 2026, 6:30 AM EDT. Centene Corp subsidiaries have initiated community-focused programs targeting behavioral health, job training, housing support, and diabetes care, aiming to assist underserved populations across major U.S. markets. These efforts come as Centene shares (NYSE:CNC) remain under pressure, with a recent price of $35.57, down 13.7% in the past month and 40.3% over one year. Investors should monitor these initiatives closely for insights into Centene's regulatory relations and potential impact on medical loss ratios and membership retention. Despite current headwinds, the stock trades nearly 17% below analyst targets and is marked as undervalued by Simply Wall St. Key risks include rising costs without clear reimbursement or measurable health outcomes.
Go toTop